Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record

BACKGROUND: In randomized controlled trials (RCTs), colesevelam HCI, added to other anti-diabetic therapy, reduced hemoglobin A1C by approximately 0.3% to 0.4% over 16- to 26-weeks compared with an increase of approximately 0.1% to 0.2% for placebo, for a placebo-adjusted treatment effect of approxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Richard A, Farley, Joel F, Maciejewski, Matthew L, Ye, Xin, Qian, Chunlin, Powers, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750408/
https://www.ncbi.nlm.nih.gov/pubmed/23866087
http://dx.doi.org/10.1186/1472-6823-13-24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750408/
https://www.ncbi.nlm.nih.gov/pubmed/23866087
http://dx.doi.org/10.1186/1472-6823-13-24

Ejemplares similares